Merck faces bellwether Fosamax lawsuit
The first of some 900 lawsuits filed against Merck claiming that its osteoporosis drug Fosamax causes osteonecrosis of the jaw (ONJ) is set to go to trial this week in New York, according to a story on Bloomberg.com. The complaint is considered one of three bellwether cases that could pave the way for out-of-court settlements, according to Bloomberg. Merck faced about 900 Fosamax cases as of June 30, including suits

